Role of Aducanumab in the Treatment of Alzheimer’s Disease: Challenges and Opportunities
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Aducanumab is a monoclonal antibody selective for amyloid β (Aβ) aggregates. In June 2021, aducanumab became the first drug underlying the pathophysiology of Alzheimer's disease (AD) approved by the US Food and Drug Administration (FDA), under the accelerated approval pathway. The decision was based on the ability of aducanumab to remove Aβ plaques, without any evidence that the Aβ clearance is correlated with less cognitive or functional decline. This decision has generated a considerable debate in the scientific community, especially because the results from the two Phase 3 trials, EMERGE and ENGAGE, were divergent and, even after the post hoc analysis, the data were insufficient to prove aducanumab efficacy. Moreover, some researchers think that this approval will be an obstacle to the progress and also demonstrated concerns about aducanumab cost and its safety profile. The European Medicines Agency's rejection of aducanumab in December 2021 just brought more controversy over FDA's decision. Now, Biogen is designing the FDA's required confirmatory study, named ENVISION, which should be complete in 2026. Despite the controversy, the aducanumab showed to affect downstream tau pathology, which could open doors for a combination therapy approach for AD (anti-tau and anti-amyloid drug). This review summarizes the clinical development of aducanumab until regulatory agencies' decisions, the available trials data and the controversy over aducanumab approval for AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In the EMERGE experiment, when participants with AD were at risk for cognitive deterioration, there was a decrease in the amount of amyloid-beta plaques.”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [132]
In the citing paper
“Aducanumab demonstrated inconsistent outcomes in its two main clinical trials, the Phase III EMERGE and ENGAGE research investigations.”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [132]
In the citing paper
“In spite of this, the FDA granted expedited approval on the grounds of the EMERGE trial’s documented decrease in amyloid levels [132,185,186,187].”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [132]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164 · cited 1×
“According to the amyloid cascade hypothesis, the extracellular accumulation of Aβ aggregates is the leading cause of synapses dysfunction, neuroinflammation, neuronal loss and is also the trigger of tau pathology.(7) Thus, researchers believe that Aβ clearance by aducanumab is a rational mechanism to slow cognitive de…”
BackgroundThe neuropathological diagnosis of Alzheimer's disease
DeTure, M. A., & Dickson, D. W. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0333-5 · Cited by 3,329 · cited 1×
“These drugs temporary attenuate symptoms but do not target AD’s two main recognized pathological features: extracellular deposits of amyloid β (Aβ) in plaques and intracellular neurofibrillary tangles (comprised of abnormal tau protein).(3,4) On June 7, 2021, aducanumab (AduhelmTM, Biogen) became the first disease-mod…”
BackgroundAlzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204 · cited 1×
“Aducanumab: Selective Anti-Aβ Antibody Over the last 25 years, several drugs targeting Aβ have failed to show clinical efficacy in trials, including five anti-Aβ antibodies: bapineuzumab, solanezumab, crenezumab, ponezumab, and gantenerumab.(25,26) Thus, supporters of the amyloid hypothesis placed high hopes on aducan…”
BackgroundThe antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059 · cited 4×
“Aducanumab is a monoclonal antibody selective for aggregated forms of Aβ, with demonstrated efficacy in the clearance of brain Aβ plaques.(6) According to the amyloid cascade hypothesis, the extracellular accumulation of Aβ aggregates is the leading cause of synapses dysfunction, neuroinflammation, neuronal loss and i…”
BackgroundMethodInfluentialLane, C. A., Hardy, J., & Schott, J. M. (2018) · European Journal of Neurology · doi:10.1111/ene.13439 · Cited by 2,616 · cited 1×
“These drugs temporary attenuate symptoms but do not target AD’s two main recognized pathological features: extracellular deposits of amyloid β (Aβ) in plaques and intracellular neurofibrillary tangles (comprised of abnormal tau protein).(3,4) On June 7, 2021, aducanumab (AduhelmTM, Biogen) became the first disease-mod…”
Background2021 Alzheimer's disease facts and figures
(2021) · Alzheimer's & Dementia · doi:10.1002/alz.12328 · Cited by 2,201
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Cerebral amyloid angiopathy and Alzheimer disease — one peptide, two pathways
Greenberg, S. M., Bacskai, B. J., Hernandez-Guillamon, M., Pruzin, J., Sperling, R., & van Veluw, S. J. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-019-0281-2 · Cited by 947 · cited 2×
“ARIAs are abnormal findings detected in brain magnetic resonance imaging (MRI) and can present as brain edema or sulcal effusions (ARIA-E) and as intracerebral hemorrhage often accompanied by superficial hemosiderin deposits (ARIA-H).(52) Although the mechanism leading to ARIA remains not fully understood, studies sug…”
BackgroundThe Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade
Cline, E. N., Bicca, M. A., Viola, K. L., & Klein, W. L. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179941 · Cited by 870
Sperling, R. A., Jack, C. R., Black, S. E., Frosch, M. P., Greenberg, S. M., Hyman, B. T., Scheltens, P., Carrillo, M. C., Thies, W., Bednar, M. M., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.05.2351 · Cited by 857 · cited 1×
“Although the mechanism leading to ARIA remains not fully understood, studies suggest that Aβ clearance causes damage to vessel walls which increases the cerebrovascular permeability and the risk of hemorrhage.(52,53) ARIA has been associated with anti-Aβ antibodies therapies and was reported in the phase 1b trial of a…”
Background
Research works printed but not linked: 6
- World Health Organization. Global action plan on the public health response to dementia 2017–2025. Geneva: World Heal Organ; 2017: 27. Available from: http://www.who.int/mental_health/neurology/dementia/action_plan_2017_2025/en/. Accessed May 14, 2022.
- Eisai. Japan’s first committee on new drugs of the pharmaceutical affairs and food sanitation council seeks additional data; aducanumab remains under review. Eisai Global; 2021. Available from: https://www.eisai.com/news/2021/news2021101.html. Accessed April 9, 2022.
- Bussiere T, Weinreb PH, Dunstan RW, et al. Differential in vitro and in vivo binding profiles of BIIB037 and other anti-abeta clinical antibody candidates. Neurodegener Dis. 2013; 11(Suppl1): 2576.
- Biogen. Update on regulatory review of aducanumab in the European Union. Biogen. Available from: https://investors.biogen.com/news-releases/news-release-details/update-regulatory-submission-aducanumab-european-union.; 2021. Accessed April 9, 2022.
- Institute for Clinical and Economic Review. ICER issues statement on the FDA’s approval of aducanumab for Alzheimer’s disease. ICER; 2021. Available from: https://icer.org/news-insights/press-releases/icer-issues-statement-on-The-fdas-approval-of-aducanumab-for-alzheimers-disease/. Accessed November 11, 2021.
- Association AF. Aduhelm lowers tau; registry to track real-world performance | ALZFORUM. Alzforum; 2021. Available from: https://www.alzforum.org/news/conference-coverage/aduhelm-lowers-tau-registry-track-real-world-performance. Accessed February 1, 2022.
Cited by
Items 101–183 of 183
Zhai, T., Krass, E., Zhang, F., & Huang, Z. J. (2023) · Frontiers in Systems Biology · doi:10.3389/fsysb.2023.1188430 · Cited by 7
“The accelerated approval of accumulation is controversial (Vaz et al., 2022).”
BackgroundA Comprehensive Review on Potential Molecular Drug Targets for the Management of Alzheimer's Disease
Sharma, C., & Mazumder, A. (2024) · Central Nervous System Agents in Medicinal Chemistry · doi:10.2174/0118715249263300231116062740 · Cited by 4
Rustage, K., Rai, N., Sinha, S. K., Goyal, J., Chouhan, P., Baniya, B., Dubey, D., Singhal, R., Malani, P., Pareek, A., et al. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-04910-9 · Cited by 5
Lee, S., Lim, C. K., Kim, J., Kim, J., Jin, H. K., Bae, J., & Jeon, J.-W. (2025) · Biomedicines · doi:10.3390/biomedicines13051169 · Cited by 4
Recent Treatment Strategies in Alzheimer's Disease and Chronic Traumatic Encephalopathy
Lucke-Wold, B. P. (2022) · Biomedical Research and Clinical Reviews · doi:10.31579/2692-9406/128 · Cited by 5
“Despite its controversy, the drug was found to have a downstream effect on p-tau levels in cerebrospinal fluid (CSF), which has major implications in the treatment of other neurodegenerative disorders aberrantly expressing p-tau, such as CTE [15,16].”
BackgroundDesign, Synthesis and Evaluation of Catechol-Based Amyloid Beta Aggregation Inhibitors
Konno, H., & Teruya, K. (2023) · Heterocycles · doi:10.3987/rev-22-999 · Cited by 4
M., M. A.-A., Hassan, M. S., & Mohamed, F. A. S. (2024) · International Youth Conference on Radio Electronics, Electrical and Power Engineering (REEPE) · doi:10.1109/reepe60449.2024.10479753 · Cited by 5
“Caregiver burden is substantial due to the gradual loss of cognitive function, necessitating specialized support and interventions [18].”
BackgroundAlzheimer’s disease: unraveling role of xanthone derivatives and nanocarriers
Suhaili, I. N. A., Yow, H.-Y., Mah, S. H., Huri, H. Z., & Tan, S. L. J. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04446-8 · Cited by 4
Tseng, T., Liaw, C., Shiao, Y., Huang, Y.-I., Cheng, Y.-H., Chen, W.-C., & Tsai, K. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1673532 · Cited by 4
Sanchez-Rodriguez, D., Gonzalez-Figueroa, I., & Alvarez-Berríos, M. P. (2023) · Pharmaceuticals · doi:10.3390/ph16060820 · Cited by 7
“Although this drug is a promising treatment, it induces severe side effects such as brain swelling or bleeding in the brain [16].”
BackgroundOne step beyond the lab and clinic: “walking the dementia conversation”
Zegarra-Valdivia, J. A., Peres, F. A., Kornhuber, A., Arshad, F., & Paredes-Manrique, C. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1284692 · Cited by 3
“There are currently two drugs that the scientific community and the US Food and Drug Administration (FDA) have paid attention to for the treatment of Alzheimer’s dementia: lecanemab (7, 8) and aducanumab (9–11).”
BackgroundAljehani, N., Al‐Gunaid, S. T., Hobani, A. H., Alhinti, M. F., Khubrani, Y., Abu-Hamoud, L. M., Alrayes, A. A., Alharbi, L. B., Sultan, A. A., Turkistani, D. A., et al. (2024) · Cureus · doi:10.7759/cureus.68008 · Cited by 5
“As noted in a study by Vaz et al., the ability of aducanumab to impact downstream tau pathology may pave the way for the use of combination therapies (drugs that target both tau and amyloid) to treat AD [17].”
ResultArmstrong, C., Luo, D., Gretzinger, A., Pandey, D., Lipchik, A. M., Todi, S. V., & Dutta, A. K. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00220 · Cited by 3
Thitilertdecha, P., & Brimson, J. M. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-230994 · Cited by 4
Barnes, J. N., Burns, J. M., Bamman, M. M., Billinger, S. A., Bodine, S. C., Booth, F. W., Brassard, P., Clemons, T. A., Fadel, P. J., Geiger, P. C., et al. (2022) · Brain Plasticity · doi:10.3233/bpl-220146 · Cited by 4
“Indeed, the recently approved monoclonal 52 anti-amyloid antibody aducanumab has unclear ther53 apeutic efficacy ([6].”
BackgroundWang, J., Shen, Y., Cong, Q., Zhang, J., Wang, Y., Jia, J., & Yan, F. (2024) · Nano Today · doi:10.1016/j.nantod.2024.102396 · Cited by 3
Sharma, A., Rudrawar, S., Sharma, A., Bharate, S. B., & Jadhav, H. R. (2024) · RSC Advances · doi:10.1039/d4ra03589e · Cited by 3
An overview on the impact of viral pathogens on Alzheimer's disease
AmeliMojarad, M., AmeliMojarad, M., & Cui, X. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102615 · Cited by 4
The role of massive demographic databases in intractable illnesses: Denomics for dementia
Stecker, M. M., Peltier, M. R., & Reiss, A. B. (2022) · AIMS Public Health · doi:10.3934/publichealth.2022043 · Cited by 3
“has significantly modified the trajectory of inexorable decline [4–6] Aducanumab, an amyloid-clearing monoclonal antibody, was recently approved by the FDA, but is highly controversial [7].”
BackgroundIs screening for Alzheimer’s disease ready for prime time? Ask Wilson and Jungner
Chatanaka, M. K., Loren, M., & Diamandis, E. P. (2025) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2025.2533860 · Cited by 3
“The efficacy of Aducanumab on slowing cognitive and functional decline is questionable [35].”
Gentry, E., Islam, M. T., Xue, H., Cao, K., & Nemes, P. (2025) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2025.101490 · Cited by 2
Das, S. K., Bashir, B., Kolekar, K. A., Harish, V., Patle, D., Vishwas, S., Mittal, N., Jha, S. K., Kumar, P., Gupta, G. K., et al. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.103000 · Cited by 4
Mishra, A., Satapathy, B. S., & Sahu, P. K. (2026) · Discover Nano · doi:10.1186/s11671-026-04528-3 · Cited by 5
Emerging Role of Medicinal Herbs on Alzheimer’s Disease and Memory Deficits
Naeem, S., Khan, S. S., Shafiq, Y., & Kashif, S. S. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1006325 · Cited by 3
Wu, S., Qi, Y., Jiang, C., & Zheng, J. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2448205 · Cited by 3
“Amyloid-related imaging abnormalities (ARIA) are the most common AEs of aducanumab, which can be manifested as brain edema or sulcal effusions (ARIA-E) and as intracerebral hemorrhage often accompanied by superficial hemosiderin deposits (ARIA-H) [10].”
Chinnappan, D., Kuppamuthu, A., Sivanandam, M., Kandasamy, S., Krishnan, M., & Elangovan, N. (2025) · ChemistrySelect · doi:10.1002/slct.202405631 · Cited by 3
Liu, M., Zhu, L., Li, F., Shi, X., Shen, Y.-F., & Liu, M. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.06.579113 · Cited by 2
Chen, A., Li, Q., Huang, Y., Li, Y., Chuang, Y.-N., Hu, X., Guo, S., Wu, Y., Guo, Y. M., & Bian, J. (2024) · medRxiv · doi:10.1101/2024.02.10.24302621 · Cited by 2
Monoclonal antibody therapy in Alzheimer’s disease: an overview and vision
Bentley, J. H., Bishop, L. E., & Broussard, J. I. (2024) · Brain Network and Modulation · doi:10.4103/bnm.bnm_14_23 · Cited by 2
Recent updates on immunotherapy in neurodegenerative diseases
Salunkhe, J., & Ugale, R. R. (2024) · Brain Research · doi:10.1016/j.brainres.2024.149205 · Cited by 2
Antibodies against Alzheimer's: Pioneering a New Era in Treatment Strategies
Verma, M., Singh, N. K., & Siddique, M. U. M. (2025) · Current Bioactive Compounds · doi:10.2174/0115734072347198241226113039 · Cited by 1
A genetically encoded selection for amyloid-β oligomer binders
Lee, B., Mannone, J. A., & Wang, T. (2025) · Nature Chemical Biology · doi:10.1038/s41589-025-01975-4 · Cited by 3
“The recent success of clinical trials leading to the approval of the first AD-modifying therapies has led to renewed interest in Aβ as a target 65,66 .”
Wiest, R., Radojewski, P., Lieb, J., Psychogios, M., Benzinger, T. L. S., Franceschi, A. M., Wanke, I., Draganski, B., Kurz, F. T., & Lövblad, K. (2025) · Neurodegenerative Diseases · doi:10.1159/000549521 · Cited by 2
“…neurological symptoms, including: headache, dizziness or gait disturbances, confusion or mental status changes (including disori-entation and cognitive fluctuations), nausea or vomiting, or focal neurological deficits (such as hemiparesis, aphasia, or visual disturbances in severe cases) [23].”
Machiels, Q., Duchateau, C., & Waeytens, J. (2025) · Biophysical Chemistry · doi:10.1016/j.bpc.2025.107551 · Cited by 1
“However, controversies surround these mAb, as clinical outcomes are unclear [24,25]. explanation to this lies in the fact that the selectivity of these mAb towards is unclear, highlighting the need for rational drug-designed anti-A -mAb A paper about the developments in life sciences by AFM-IR…”
Mechanisms to medicines: navigating drug repurposing strategies in Alzheimer’s disease
Khan, S. A., Raza, K., Tiwari, P., El‐Tanani, M., Rabbani, S. A., & Parvez, S. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1676065 · Cited by 4
“…trial outcomes suggest that aducanumab’s ability to reduce amyloid plaques has been linked to a slower decline in cognitive abilities, as assessed by clinical metrices utilizing Mini-Mental State Examination (MMSE) and Clinical Dementia Rating-Sum of Boxes (CDR-SB) scores (Vaz et al., 2022).”
Huang, S., & Guo, Y. (2026) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823261422205 · Cited by 1
“33 Since then, the EMA has approved other anti-amyloid monoclonal antibodies, including lecanemab and donane-mab, following the availability of additional trail data indicating modest clinical bene fi t. Biogen ’ s ENVISION study, a validation study assessing the safety and ef fi cacy of long-term…”
A universal phase-plane model for in vivo protein aggregation
Cotton, M. W., Goriely, A., Klenerman, D., & Meisl, G. (2026) · The Journal of Chemical Physics · doi:10.1063/5.0312752 · Cited by 3
“…models are essential for understanding the effect of several therapeutic interventions currently in development: Promising monoclonal antibody therapies, such as lecanemab 7 , do-nanemab 8 , and aducanumab 9 aim to support the body’s removal mechanisms by targetting aggregates of the A β peptide.”
Lin, Y., Hsu, T., Kao, Y., Thompson, T., Carvalho, A. F., Stubbs, B., Tseng, P., Hsu, C., Yang, F.-C., Tsai, C., et al. (2026) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2025-336691 · Cited by 1
The Erythrocyte - A Unique Cell
Rajashekaraiah, V. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.101007 · Cited by 4
ADUCANUMAB NO TRATAMENTO DA DOENÇA DE ALZHEIMER
do Amaral, A. T., Iamaguti, F. T., Ferreira, I., Almeida, J., Iamaguti, J. ́., da Silva, M. N. B., Pereira, P. N., de Oliveira, É. À., Rocha, C. M., & de Oliveira, A. F. F. (2023) · RECIMA21 - Revista Científica Multidisciplinar · doi:10.47820/recima21.v4i9.4023 · Cited by 1
Yao, Z., Mao, W., Wang, Z., & Zhang, G. (2023) · International Symposium on Artificial Intelligence for Medicine Sciences (ISAIMS) · doi:10.1145/3644116.3644186 · Cited by 1
“Advancements in early and differential diagnosis would meaningfully impact research efforts and clinical care for patients living with dementia [2, 3].”
BackgroundYou, H., Song, Y., Yang, Y. A., Wang, X., Pan, S., Huang, J., Shao, Q., Shi, D., Li, B., Li, J., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116800 · Cited by 1
Wojcieszak, J. (2023) · Farmacja Polska · doi:10.32383/farmpol/166243 · Cited by 1
Błach, A. (2023) · Aktualności Neurologiczne · doi:10.15557/an.2023.0024 · Cited by 1
Emerging Alzheimer’s therapies: clinical efficacy versus economic feasibility
Shahid, N., Azhar, L., Hussain, I., & Khan, M. S. (2026) · Neurodegenerative Disease Management · doi:10.1080/17582024.2026.2617857 · Cited by 1
Erythrocytes as Messengers for Information and Energy Exchange between Cells
Johansson, E., & Falk, A. B. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.108321
Lange‐Asschenfeldt, C., & Benkert, O. (2023) · Springer eBooks · doi:10.1007/978-3-662-67685-1_6
Ferroptosis Modulators: A Potential Therapeutic Target in Alzheimer’s Disease
Singh, G., Rana, N. K., Mishra, I., & Modi, G. P. (2023) · Springer eBooks · doi:10.1007/978-981-99-6038-5_14
Systematic Overview: AD Pathology and Recent Pharmacological Advances
Luo, T. (2024) · Transactions on Materials Biotechnology and Life Sciences · doi:10.62051/sp72fq46
“The pro-inflammatory cytokines TNF-α, IL-1β, and IL-6 that are released by activated microglia can also be released by activated astrocytes and also promote inflammation, but they also lead to oxidative stress and synaptic loss [13].”
BackgroundAnálise da eficácia clínica do fármaco Aducanumab no tratamento da Doença de Alzheimer
Turke, C. C., Neto, V. C., Zumbano, G. M., Shimada, T., Akamine, M. Y. E., Camargo, R. M., Morelli, S. D. A., & Estrela, H. F. G. (2024) · Brazilian Journal of Health Review · doi:10.34119/bjhrv7n3-115
Hugging it out: Targeting oxytocin in alzheimer’s disease
Koulousakis, P. (2024) · Research Publications (Maastricht University) · doi:10.26481/dis.20240523pk
Research Progress and Future Development Directions of Alzheimer’s Disease
Jin, J. (2025) · Theoretical and Natural Science · doi:10.54254/2753-8818/2024.la19856
Co-Deposited Proteins in Alzheimer’s Disease as a Potential Treasure Trove for Drug Repurposing
Apostolakou, A. E., Douska, D. E., Litou, Z. I., Trougakos, I. P., & Iconomidou, V. A. (2025) · Molecules · doi:10.3390/molecules30081736
“…what is considered by many as a controversial decision, the FDA approved the drug aducanumab , a monoclonal antibody targeting amyloid-β aggregates [31]. with little Now, during the writing of this publication, the FDA is approving yet another drug, lecanemab , with a similar mechanism of action…”
Bouvenot, G. (2025) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2025.02.009 · Cited by 2
The omics techniques used in perineuronal nets research
Huang, S., Tang, J., Wu, X. M., Xu, H., Li, S., Li, H., Zhang, S., Xie, G., Wang, T., Pan, X., et al. (2025) · Experimental Neurology · doi:10.1016/j.expneurol.2025.115369 · Cited by 1
Deciphering the molecular and neuropathological dimensions of dementia
Dutta, S., Bhattacharjee, P., Noori, S., Adhikari, N., Dule, S., Soyel, M. I., Besra, M., Borah, S., & Gupta, P. (2025) · NPG. Neurologie, psychiatrie, gériatrie/NPG · doi:10.1016/j.npg.2025.05.002
Biomarkers and therapeutic targets in early Alzheimer’s disease: an Olink proteomics study
Wei, J., Ni, H., Liu, W., Xu, H., Wang, C., Geng, G., He, Z., & Chen, G. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1615152 · Cited by 1
“Up to now, only three effective targeted drugs, namely Lecanemab, Donannan, and Aducanumab, have been approved by the Food and Drug Administration (FDA) of the United States for the treatment of AD (27, 28).”
Antibodies targeting amyloid-β and Tau oligomers in Alzheimer’s disease
Chinnathambi, S., Rangappa, N., & Chandrashekar, M. (2025) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2025.10.002
Gawai, M., Nistane, N. T., Tatode, A., Qutub, M., Umekar, M. J., Premchandani, T., & Taksande, J. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102994 · Cited by 1
Wang, X., Xie, Y., Fan, X., Wu, X., Wang, D., & Zhu, L. (2024) · Figshare · doi:10.6084/m9.figshare.26728936
Wang, X., Xie, Y., Fan, X., Wu, X., Wang, D., & Zhu, L. (2024) · Figshare · doi:10.6084/m9.figshare.26728939
Qian, C., Shang, Y., Cai, L., Zhang, Y., Chu, C., Guo, Z., & Wang, X. (2025) · Inorganic Chemistry Frontiers · doi:10.1039/d5qi01746g
Sourcing and screening human antibody repertoires for discovering biotherapeutics
Abdiche, Y. N., & Hoet, R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00062-5
Nadkarni, S. G., & Dessai, S. N. (2026) · Food and Humanity · doi:10.1016/j.foohum.2026.100993
The influence of bapineuzumab and semagacestat on rapid progressors: A retrospective cohort study
Harris, K., Shyer, M. N., Wang, D., He, E., Cattani, M., Zhang, C., Farrell, C. M., Jiang, X., Kim, Y., & Schulz, P. E. (2026) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2026.100483 · Cited by 1
“While aducanumab was designated for accelerated approval by the FDA because it was shown to decrease the amount of A β plaque in the brain, the cognitive benefit was mixed and only met primary or secondary endpoints in one of the two clinical trials [5,19,20].”
Roy, D., Kakoti, B. B., & Rymbai, E. (2026) · Discover Chemistry. · doi:10.1007/s44371-026-00508-9
“These medications show promise in clearing amyloid-β aggregates, but come with significant side effects like amyloid-related imaging abnormalities (ARIA), infusion reactions, headaches, and increased risk of falls [11, 12].”
Probing APP Cleavage and Amyloid-β Assembly via Synthetic MUC-Type O -Glycosylated APP Glycopeptides
Vela, N., Mundim, G. D. N., Regmi, D., Boneva, I., Ayyalasomayajula, R., Vezzi, M. E., Borraez, V. S., Crowder, A., Coronel-Zegarra, A., Shafi, H., et al. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00608
From bench to bedside: Emerging therapeutics for alzheimer's disease in clinical trials
Verma, M., & Singh, N. K. (2026) · Metabolic Brain Disease · doi:10.1007/s11011-026-01793-0
Huang, Y., Li, Q., Chen, A., Li, Y., Chuang, Y.-N., Hu, X., Guo, S. J., He, X., Pang, Y., Zhou, J., et al. (2026) · JAMIA Open · doi:10.1093/jamiaopen/ooag060 · Cited by 2
Ji, T., Wang, L. Y., Weng, X., Lu, C., Gao, Y. Z., Yu, K., He, J., Shen, X., & Gao, X. Z. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1848282
FDA Approval of Donanemab‐azbt: A New Dawn in Alzheimer's Disease Treatment
Riaz, R., Fatima, M., Ramzan, S., Rathi, D., Fatima, F., farooq, M., Shaukat, A. F., Khaliq, N., & Akilimali, A. (2026) · Health Science Reports · doi:10.1002/hsr2.72688
Advances in 3D cell culture models for Alzheimer’s Disease drug discovery
Valdivia-Aviña, K., Ochoa-Hugo, S. E., Hernández-Sapiéns, M. A., & Canales-Aguirre, A. A. (2026) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2026.2691833
“For this reason, new treatments are still being developed as potential therapeutic strategies for AD, highlighting that the search for more effective therapies is in constant evolution [45,47,48].”
Treatment Using Anti-Amyloid Antibodies for Alzheimer’s Disease
Chatterjee, S., Gayen, S., & Roy, S. (2026) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898815646126010012
New Insights into Drug Development and Immunotherapy for Alzheimer’s Disease
Gayen, S., Roy, S., Uddin, M. A., & Sukul, D. (2026) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898815646126010014
Priya, L., V, & Murugaanandam, S. (2026) · International Conference on Data Science for Cyber-Physical Systems Resilience using Advanced Applications (ICDCA) · doi:10.1109/icdca69396.2026.11620499
“The AD is considered a brain dysfunction resulting from genetics/environment/epigenetics/metabolism and is a complicated disorder resulting from the interplay of various factors [5].”
Sigma-1 Receptor Ligand Blarcamesine (ANAVEX 2-73) for Alzheimer’s Disease: A Systematic Review
Brimson, S., Thitilertdecha, P., Kumaree, K. K., & Brimson, J. M. (2026) · CNS Drugs · doi:10.1007/s40263-026-01327-3
THERAPY FOR ALZHEIMER’S DISEASE - FOCUS ON LECANEMAB
Jońca, M., Majchrowicz, G., Kurys, N., Piekarska, W., Litke, S., & Gołacka, K. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(51).2026.5795
The Great Transatlantic Divide: The Case of Experimental Neuropharmacology
Colosimo, C. (2026) · Clinical Drug Investigation · doi:10.1007/s40261-026-01593-5
Molecular and genetic basis of alzheimer’s disease and emerging treatment Modalities
Varshney, H., & Siddique, Y. H. (2026) · Neurodegenerative Disease Management · doi:10.1080/17582024.2026.2739332
Nobukawa, S., Ikeda, T., Kikuchi, M., & Takahashi, T. (2026) · International Conference on Emerging Techniques in Computational Intelligence (ICETCI) · doi:10.1109/icetci71772.2026.11710718
“Although therapeutic strategies remain actively debated, the importance of early diagnosis and intervention to slow disease progression has been increasingly recognized [28].”
Metadata
- Authors
- Vaz, M., Silva, V., Monteiro, C., & Silvestre, S.
- Affiliations
- University of Beira Interior (PT)
- Corresponding author
- Vaz, Miguel
- Venue
- Clinical Interventions in Aging
- Publisher
- Informa UK Limited
- Published
- 2022-05
- Volume
- Volume 17
- Pages
- 797-810
- ISSN
- 1176-9092 (ISSN-L)
- 1178-1998
- PMC
- PMC9124475
- OpenAlex
- W4280613528
- Cited by
- 183
- References
- 48
- Citations by year
- 2026: 26 · 2025: 42 · 2024: 58 · 2023: 41 · 2022: 16
- FWCI
- 5.40
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Clinical Interventions in Aging (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- Programa Operacional Regional do Centro (CENTRO-01-0145-FEDER-000013)
- Fundação para a Ciência e a Tecnologia (UID/Multi/00709, UID/Multi/00709/2019, 01-0145, COMPETE, POCI-01-0145, POCI-01-0145-FEDER-, COMPETE_2020, 00709/2019, POCI-01-, POCI-01-0145-FEDER- 007491, CENTRO-01-0145-FEDER-000013, 007491, 00709)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- aducanumab, Alzheimer's disease, amyloid-beta, anti-amyloid monoclonal antibodies, accelerated approval, tau pathology, combination therapy, drug safety, drug costs, regulatory decision-making
- MeSH terms
- Alzheimer Disease, Humans, United States, United States Food and Drug Administration, Amyloid beta-Peptides, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

